Healthcare Services

Global Cell Free DNA (cfDNA) Testing Industry Trends and Market Growth Forecast for 2026–2030

March 31, 2026March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Cell Free DNA (cfDNA) Testing Market By 2030 Starting From Its 2026 Size?

The cell free dna (cfdna) testing market has experienced substantial expansion in its size over recent years. This market is projected to expand from $10.84 billion in 2025 to $13.42 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 23.8%. Factors contributing to its historical growth include the rising prevalence of cancer diagnostics, the increasing adoption of non-invasive testing methods, the expansion of prenatal screening programs, advancements in sequencing technologies, and the growing clinical acceptance of liquid biopsy.

The cell free dna (cfdna) testing market size is projected for substantial expansion in the upcoming years, with expectations to reach $28.81 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 21.0%. This projected growth throughout the forecast period can be attributed to heightened investments in precision oncology, an increasing need for early cancer detection, the broadened scope of transplant monitoring applications, the wider acceptance of personalized medicine, and greater integration of AI-driven genomic analysis. Significant developments during this period are anticipated to include the rising adoption of liquid biopsy diagnostics, an increase in the utilization of ngs-based cfdna analysis, surging demand for non-invasive prenatal testing, the expansion of oncology monitoring applications, and improved integration of bioinformatics platforms.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15757&type=smp

What Primary Drivers Are Shaping The Development Of The Cell Free DNA (cfDNA) Testing Market?

The projected increase in cancer cases is poised to drive the expansion of the cell-free DNA (cfDNA) testing market moving forward. Cancer refers to a complex set of diseases defined by the uncontrolled multiplication and spread of anomalous cells throughout the body. These cells can invade and destroy healthy tissue and, if left unchecked, can significantly compromise bodily functions. The prevalence of cancer can be attributed to an aging global population, shifts in lifestyle, various environmental factors, and improvements in detection and diagnostic technologies. cfDNA testing plays a crucial role by identifying genetic mutations associated with cancer in its early stages, often before symptoms become apparent. This early detection enables timely medical intervention, thereby enhancing patient outcomes and survival rates by pinpointing cancer when it is most treatable. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, estimated that new cancer cases are expected to exceed 35 million by 2050, representing a 77% increase over the forecasted 20 million cases in 2022. Thus, the escalating incidence of cancer is a key factor propelling the growth of the cell-free DNA (cfDNA) testing market.

Which Segment Categories Define The Cell Free DNA (cfDNA) Testing Market?

The cell free dna (cfdna) testing market covered in this report is segmented –

1) By Product: Donor-Derived Cell-Free DNA, Circulating Cell-Free Tumor DNA, Cell-Free Fetal DNA

2) By Platforms: Next Generation Sequencing (NGS), rPCR And Multiplexed PCR, qPCR And dPCR, Other platforms

3) By Application: Oncology, Non-Invasive Prenatal Test (NIPT), Gynecology, Transplantation, Other Applications

Subsegments:

1) By Donor-Derived Cell-Free DNA: Organ Transplant Monitoring, Graft Rejection Detection

2) By Circulating Cell-Free Tumor DNA: Cancer Detection, Minimal Residual Disease Monitoring, Liquid Biopsy

3) By Cell-Free Fetal DNA: Non-Invasive Prenatal Testing (NIPT), Fetal Genetic Disorder Screening

How Are Trends Impacting The Cell Free DNA (cfDNA) Testing Market?

Key companies within the cell-free DNA (cfDNA) testing market are concentrating on advancing innovative technologies, specifically liquid biopsy tests, which deliver improved sensitivity, specificity, and efficiency in detecting cancer-related mutations and genetic alterations. Liquid biopsy tests are diagnostic procedures that enable oncologists to assess circulating cell-free DNA originating from tumor cells, thereby facilitating personalized, targeted therapy plans. For instance, in May 2023, Laboratory Corporation of America Holdings (Labcorp), a US-based life sciences company, introduced Labcorp Plasma Focus, a novel liquid biopsy test tailored for patients with advanced or metastatic solid tumors. This test analyzes circulating cell-free DNA (cfDNA) released by tumor cells from a standard blood draw, providing a minimally invasive option and rapid results. It expands access to precision oncology by identifying clinically actionable biomarkers across numerous common cancers, such as non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma.

Who Are The Top Companies Competing In The Cell Free DNA (cfDNA) Testing Market?

Major companies operating in the cell free dna (cfdna) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC

Read the full cell free dna (cfdna) testing market report here:

https://www.thebusinessresearchcompany.com/report/cell-free-dna-cfdna-testing-global-market-report

How Does The Cell Free DNA (cfDNA) Testing Market Perform Across Major Global Regions?

North America was the largest region in the cell-free DNA (cfDNA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free dna (cfdna) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cell Free DNA (cfDNA) Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15757&type=smp

Browse Through More Reports Similar to the Global Cell Free DNA (cfDNA) Testing Market 2026, By The Business Research Company

Cell Counting Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-counting-global-market-report

Cell Cultures Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-cultures-global-market-report

Cell Separation Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-separation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795